Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Original Article



Effect of piperine and its analogs on pharmacokinetic properties of sorafenib tosylate: Bioanalytical method development and validation

Anshuly Tiwari, Kakasaheb R. Mahadik, Satish Y. Gabhe.

Abstract
Sorafenib tosylate (ST) is a drug of choice for the treatment of advanced hepatocellular carcinoma. The bioavailability of ST varies from 29% to 38% due to the presence of food, medication, and other factors. Moreover, the dose of ST (400 mg twice a day) is also higher due to its poor bioavailability. Piperine is known as a natural bioenhancer, and the use of a bioenhancer ultimately leads to a synergistic effect. In this study, the development and validation of a precise, accurate, and reproducible bioanalytical method was carried out using reversed-phase high-performance liquid chromatography (RP-HPLC). The objective of the study is to determine the effect of piperine and its analogs on the pharmacokinetics of ST using rats. The dose of ST alone and in combination with piperine and its analogs, given orally to male Wistar rats in suspension form, and the drug plasma concentration was examined using a validated RP-HPLC bioanalytical method. The separation of piperine and ST was achieved on the Chromatopak basic C18 HPLC column with the dimension of 250 mm × 4.6 mm × 5 ÎĽm, guarded along with the phenomenex guard column using ACN:Water:Formic Acid (70:29.5:0.5 v/v) as the mobile phase at 280 nm (isosbestic point of piperine and ST). The pharmacokinetic data of ST, along with piperine, exhibit a significant increase in area under the curve (AUC) of ST (1.66-fold), while the two derivatives of piperine (5a and 5d) exhibited almost double the increase in AUC compared to piperine (2.58 and 2.42-fold, respectively).

Key words: Sorafenib Tosylate (ST), Piperine, Bioenhancer, Cancer, Hepatocellular Carcinoma, Pharmacokinetics, Bioavailability.



Similar Articles

Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies.
Dillon J, Ademuyiwa FO, Barrett M, Moss HA, Wignall E, Menendez C, Hughes KS, Plichta JK
Surgical oncology clinics of North America. 2022; 31(1): 109-126

Financial Toxicity and Shared Decision Making in Oncology.
Greenup RA
Surgical oncology clinics of North America. 2022; 31(1): 1-7

Epsin 3 potentiates the NF‑κB signaling pathway to regulate apoptosis in breast cancer.
Wu Q, Li Q, Zhu W, Zhang X, Li H
Molecular medicine reports. 2022; 25(1):

Organelle-inspired supramolecular nanomedicine to precisely abolish liver tumor growth and metastasis.
Zhan J, Wang Y, Ma S, Qin Q, Wang L, Cai Y, Yang Z
Bioactive materials. 2022; 9(): 120-133

Contributing factors common to COVID‑19 and gastrointestinal cancer.
Kostoff RN, Briggs MB, Kanduc D, Shores DR, Kovatsi L, Drakoulis N, Porter AL, Tsatsakis A, Spandidos DA
Oncology reports. 2022; 47(1):


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.



ScopeMed Web Sites